Target- |
Mechanism- |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.IN |
First Approval Date15 Apr 2017 |
A Prospective, Randomized, Double-Blind, Vehicle-Controlled Study To Evaluate The Safety and Efficacy of Diperoxochloric Acid (DPOCl, DermaPro®) In Patients With Non-Healing Diabetic Foot Ulcers - Phase III Study of DermaPro® for the Treatment of Diabetic Foot Ulcer
A Randomised Dose Finding Study Comparing The Safety And Efficacy Of three blinded doses of Diperoxochloric Acid (DPOCl, DermaPro®) and A Standard Moist Wound Dressing In Patients With Non-Healing Diabetic Foot Ulcers - DermaPro® versus standard moist wound dressing in patients with diabetic foot ulcers
A multicentre, double-blind, randomised, controlled phase II/III study to evaluate the efficacy and safety of the new wound healing solution Diperoxochloric acid (DPOCl, DermaPro®) in patients with venous leg ulcer (ulcus cruris) - DPOCl versus isotonic sodium chloride solution in patients with ulcus cruris
100 Clinical Results associated with Dermatools Biotech GmbH
0 Patents (Medical) associated with Dermatools Biotech GmbH
100 Deals associated with Dermatools Biotech GmbH
100 Translational Medicine associated with Dermatools Biotech GmbH